In this study, we evaluated the positive rate, clinicopathological significance, and prognostic impact of s‐p53‐Abs and s‐NY‐ESO‐1‐Abs in ESCC, gastric cancer, and HCC. This evidence concerns the gene TP53 and gastric cancer.